Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review

Pharmacology and Therapeutics

Volumn 141, Issue 1, 2014, Pages 92-116

  Stingl, J C ^a   Bartels, H ^b   Viviani, R ^b   Lehmann, M L ^a   Brockmoller J ^c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Drug metabolism; Pharmacogenetics; Pharmacogenetics based dose adjustments; Polymorphism; UDP glucuronosyltransferases; UGT1A1

Indexed keywords

ACETYLSALICYLIC ACID; ATAZANAVIR; ATORVASTATIN; CARBAMAZEPINE; CYCLOSPORIN; DEFERIPRONE; EFAVIRENZ; ETOPOSIDE; FIRTECAN; GLUCURONOSYLTRANSFERASE; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; IRINOTECAN; LAMOTRIGINE; LORAZEPAM; METHADONE; METHOTREXATE; MORPHINE; MYCOPHENOLIC ACID; OLANZAPINE; OXAZEPAM; PARACETAMOL; RALTEGRAVIR; RAPAMYCIN; SIPOGLITAZAR; SORAFENIB; TACROLIMUS; TELMISARTAN; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE; ANALGESIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; DRUG; PSYCHOTROPIC AGENT; URIDINE DIPHOSPHATE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AFRICA; AREA UNDER THE CURVE; ASIAN; BLOOD TOXICITY; CAUCASIAN; CHILDHOOD LEUKEMIA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG METABOLISM; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCURONOSYLTRANSFERASE 1A1 GENE; GLUCURONOSYLTRANSFERASE 1A3 GENE; GLUCURONOSYLTRANSFERASE 1A4 GENE; GLUCURONOSYLTRANSFERASE 1A6 GENE; GLUCURONOSYLTRANSFERASE 1A9 GENE; GLUCURONOSYLTRANSFERASE 2B15 GENE; GLUCURONOSYLTRANSFERASE 2B17 GENE; GLUCURONOSYLTRANSFERASE 2B7 GENE; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTENSION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MEDLINE; METASTATIC COLORECTAL CANCER; MIXED INFECTION; MYOPATHY; PHARMACOGENETICS; POLYMORPHIC LOCUS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TUBERCULOSIS; GENETICS; META ANALYSIS; METABOLISM; PHARMACOKINETICS;

ANALGESICS; ANTI-HIV AGENTS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS; URIDINE DIPHOSPHATE;

EID: 84890561172     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.09.002     Document Type: Review

References (240)

1. K. Akaba, T. Kimura, A. Sasaki, S. Tanabe, T. Wakabayashi, and M. Hiroi Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese J Hum Genet 44 1999 22 25
2. M. Ando, Y. Ando, Y. Sekido, M. Ando, K. Shimokata, and Y. Hasegawa Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients Jpn J Cancer Res 93 2002 591 597
3. Y. Ando, H. Saka, G. Asai, S. Sugiura, K. Shimokata, and T. Kamataki UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan Ann Oncol 9 1998 845 847
4. M.J. Bailey, and R.G. Dickinson Acyl glucuronide reactivity in perspective: biological consequences Chem Biol Interact 145 2003 117 137
5. S. Baldelli, S. Merlini, N. Perico, A. Nicastri, M. Cortinovis, and E. Gotti C-440 T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation Pharmacogenomics 8 2007 1127 1141
6. E. Beutler, T. Gelbart, and A. Demina Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95 1998 8170 8174
7. C.R. Bhasker, W. McKinnon, A. Stone, A.C. Lo, T. Kubota, and T. Ishizaki Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance Pharmacogenetics 10 2000 679 685
8. M. Blanca Sanchez, J.L. Herranz, C. Leno, R. Arteaga, A. Oterino, and E.M. Valdizan UGT2B7-161C > T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study Ther Drug Monit 32 2010 177 184
9. L.R. Bomgaars, M. Bernstein, M. Krailo, R. Kadota, S. Das, and Z. Chen Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study J Clin Oncol 25 2007 4622 4627
10. P.J. Bosma, J.R. Chowdhury, C. Bakker, S. Gantla, A. de Boer, and B.A. Oostra The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome N Engl J Med 333 1995 1171 1175
11. M.A. Boyd, P. Srasuebkul, K. Ruxrungtham, P.I. Mackenzie, V. Uchaipichat, and M. Stek Jr. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir Pharmacogenet Genomics 16 2006 321 329
12. A. Brands, P.A. Munzel, and K.W. Bock In situ hybridization studies of UDP-glucuronosyltransferase UGT1A6 expression in rat testis and brain Biochem Pharmacol 59 2000 1441 1444
13. R.E. Bullingham, A.J. Nicholls, and B.R. Kamm Clinical pharmacokinetics of mycophenolate mofetil Clin Pharmacokinet 34 1998 429 455
14. N. Carulli, M. Ponz de Leon, E. Mauro, F. Manenti, and A. Ferrari Alteration of drug metabolism in Gilbert's syndrome Gut 17 1976 581 587
15. G. Casella, and R.L. Berger Statistical Interference. In (Vol. 2, pp. 242-243) 2002 Pacific Grove Duxbury
16. E. Cecchin, F. Innocenti, M. D'Andrea, G. Corona, E. De Mattia, and P. Biason Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan J Clin Oncol 27 2009 2457 2465
17. G. Chen, A.S. Blevins-Primeau, R.W. Dellinger, J.E. Muscat, and P. Lazarus Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp > Tyr) polymorphism Cancer Res 67 2007 9024 9029
18. Y. Chen, S. Chen, X. Li, X. Wang, and S. Zeng Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population Drug Metab Dispos 34 2006 1462 1467
19. Y. Chen, G.E. Kuehl, J. Bigler, C.F. Rimorin, Y. Schwarz, and D.D. Shen UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin Pharmacogenet Genomics 17 2007 571 579
20. S.K. Cho, E.S. Oh, K. Park, M.S. Park, and J.Y. Chung The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers Pharmacogenet Genomics 22 2012 598 605
21. X.M. Chu, L.F. Zhang, G.J. Wang, S.N. Zhang, J.H. Zhou, and H.P. Hao Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients Eur J Clin Pharmacol 68 2012 1395 1401
22. J.Y. Chung, J.Y. Cho, K.S. Yu, J.R. Kim, H.R. Jung, and K.S. Lim Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers Clin Pharmacol Ther 77 2005 486 494
23. J.Y. Chung, J.Y. Cho, K.S. Yu, J.R. Kim, K.S. Lim, and D.R. Sohn Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects Clin Pharmacol Ther 83 2008 595 600
24. M.H. Court, S.X. Duan, L.L. von Moltke, D.J. Greenblatt, C.J. Patten, and J.O. Miners Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms J Pharmacol Exp Ther 299 2001 998 1006
25. M.H. Court, Q. Hao, S. Krishnaswamy, T. Bekaii-Saab, A. Al-Rohaimi, and L.L. von Moltke UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver J Pharmacol Exp Ther 310 2004 656 665
26. M.H. Court, S. Hazarika, S. Krishnaswamy, M. Finel, and J.A. Williams Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction Mol Pharmacol 74 2008 744 754
27. M.H. Court, X. Zhang, X. Ding, K.K. Yee, L.M. Hesse, and M. Finel Quantitative distribution of mRNAs encoding the 19 human UDP- glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues Xenobiotica 42 2012 266 277
28. J.F. Crigler Jr., and V.A. Najjar Congenital familial nonhemolytic jaundice with kernicterus Pediatrics 10 1952 169 180
29. F.A. de Jong, D.F. Kehrer, R.H. Mathijssen, G.J. Creemers, P. de Bruijn, and R.H. van Schaik Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study Oncologist 11 2006 944 954
30. F.A. de Jong, T.J. Scott-Horton, D.L. Kroetz, H.L. McLeod, L.E. Friberg, and R.H. Mathijssen Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein Clin Pharmacol Ther 81 2007 42 49
31. C.S. Denlinger, R. Blanchard, L. Xu, C. Bernaards, S. Litwin, and C. Spittle Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors Cancer Chemother Pharmacol 65 2009 97 105
32. A.A. Desai, F. Innocenti, and M.J. Ratain UGT pharmacogenomics: implications for cancer risk and cancer therapeutics Pharmacogenetics 13 2003 517 523
33. N. Djebli, N. Picard, J.P. Rerolle, Y. Le Meur, and P. Marquet Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients Pharmacogenet Genomics 17 2007 321 330
34. J.Y. Douillard, D. Cunningham, A.D. Roth, M. Navarro, R.D. James, and P. Karasek Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047
35. T. Ebner, G. Schanzle, W. Weber, U. Sent, and J. Elliott In vitro glucuronidation of the angiotensin II receptor antagonist telmisartan in the cat: a comparison with other species J Vet Pharmacol Ther 36 2013 154 160
36. L. Elens, B. Vandercam, J.C. Yombi, D. Lison, P. Wallemacq, and V. Haufroid Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients Pharmacogenomics 11 2010 1223 1234
37. M. Finel, X. Li, D. Gardner-Stephen, S. Bratton, P.I. Mackenzie, and A. Radominska-Pandya Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity J Pharmacol Exp Ther 315 2005 1143 1149
38. C. Ghosh, M. Hossain, V. Puvenna, J. Martinez-Gonzalez, A. Alexopolous, and D. Janigro Expression and functional relevance of UGT1A4 in a cohort of human drug-resistant epileptic brains Epilepsia 54 9 2013 1562 1570
39. R. Ghotbi, B. Mannheimer, E. Aklillu, A. Suda, L. Bertilsson, and E. Eliasson Carriers of the UGT1A4 142 T > G gene variant are predisposed to reduced olanzapine exposure - an impact similar to male gender or smoking in schizophrenic patients Eur J Clin Pharmacol 66 2010 465 474
40. B.E. Gidal, R. Sheth, J. Parnell, K. Maloney, and M. Sale Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy Epilepsy Res 57 2003 85 93
41. K.L. Gill, J.B. Houston, and A. Galetin Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin Drug Metab Dispos 40 2012 825 835
42. H. Girard, M.H. Court, O. Bernard, L.C. Fortier, L. Villeneuve, and Q. Hao Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver Pharmacogenetics 14 2004 501 515
43. C. Guillemette Pharmacogenomics of human UDP-glucuronosyltransferase enzymes Pharmacogenomics J 3 2003 136 158
44. C. Guillemette, E. Levesque, M. Harvey, J. Bellemare, and V. Menard UGT genomic diversity: beyond gene duplication Drug Metab Rev 42 2010 24 44
45. M.I. Gulcebi, A. Ozkaynakci, M.Z. Goren, R.G. Aker, C. Ozkara, and F.Y. Onat The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy Epilepsy Res 95 2011 1 8
46. Y. Guo, C. Hu, X. He, F. Qiu, and L. Zhao Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy Drug Metab Pharmacokinet 27 2012 536 542
47. D. Guo, L.F. Pang, Y. Han, H. Yang, G. Wang, and Z.R. Tan Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers Eur J Clin Pharmacol 69 2012 843 849
48. J.Y. Han, H.S. Lim, Y.H. Park, S.Y. Lee, and J.S. Lee Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer Lung Cancer 63 2009 115 120
49. J.Y. Han, H.S. Lim, E.S. Shin, Y.K. Yoo, Y.H. Park, and J.E. Lee Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin J Clin Oncol 24 2006 2237 2244
50. S. Hazama, A. Nagashima, H. Kondo, S. Yoshida, R. Shimizu, and A. Araki Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism Cancer Sci 101 2010 722 727
51. X. He, L.M. Hesse, S. Hazarika, G. Masse, J.S. Harmatz, and D.J. Greenblatt Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion Br J Clin Pharmacol 68 2009 721 730
52. M. Holthe, T.N. Rakvag, P. Klepstad, J.R. Idle, S. Kaasa, and H.E. Krokan Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients Pharmacogenomics J 3 2003 17 26
53. J.M. Hoskins, R.M. Goldberg, P. Qu, J.G. Ibrahim, and H.L. McLeod UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 99 2007 1290 1295
54. C.C. Hung, J.L. Ho, W.L. Chang, J.J. Tai, T.J. Hsieh, and Y.W. Hsieh Association of genetic variants in six candidate genes with valproic acid therapy optimization Pharmacogenomics 12 2011 1107 1117
55. F. Innocenti, D.L. Kroetz, E. Schuetz, M.E. Dolan, J. Ramirez, and M. Relling Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics J Clin Oncol 27 2009 2604 2614
56. L. Iyer, S. Das, L. Janisch, M. Wen, J. Ramirez, and T. Karrison UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity Pharmacogenomics J 2 2002 43 47
57. S.R. Jada, R. Lim, C.I. Wong, X. Shu, S.C. Lee, and Q. Zhou Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C> A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients Cancer Sci 98 2007 1461 1467
58. L.A. Johnson, W.S. Oetting, S. Basu, S. Prausa, A. Matas, and P.A. Jacobson Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors Eur J Clin Pharmacol 64 2008 1047 1056
59. Y. Kawato, M. Aonuma, Y. Hirota, H. Kuga, and K. Sato Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res 51 1991 4187 4191
60. C.D. King, G.R. Rios, J.A. Assouline, and T.R. Tephly Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate Arch Biochem Biophys 365 1999 156 162
61. J. Kirchheiner, and J. Brockmoller Clinical consequences of cytochrome P450 2C9 polymorphisms Clin Pharmacol Ther 77 2005 1 16
62. J. Kirchheiner, K. Brosen, M.L. Dahl, L.F. Gram, S. Kasper, and I. Roots CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages Acta Psychiatr Scand 104 2001 173 192
63. J. Kirchheiner, K. Nickchen, M. Bauer, M.L. Wong, J. Licinio, and I. Roots Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response Mol Psychiatry 9 2004 442 473
64. S. Kishi, C. Cheng, D. French, D. Pei, S. Das, and E.H. Cook Ancestry and pharmacogenetics of antileukemic drug toxicity Blood 109 2007 4151 4157
65. S. Kishi, W. Yang, B. Boureau, S. Morand, S. Das, and P. Chen Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia Blood 103 2004 67 72
66. K.M. Knights, A. Rowland, and J.O. Miners Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) Br J Clin Pharmacol 76 4 2013 587 602
67. S. Krishnaswamy, Q. Hao, A. Al-Rohaimi, L.M. Hesse, L.L. von Moltke, and D.J. Greenblatt UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S) J Pharmacol Exp Ther 313 2005 1340 1346
68. G.E. Kuehl, J. Bigler, J.D. Potter, and J.W. Lampe Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes Drug Metab Dispos 34 2006 199 202
69. D.R. Kuypers, M. Naesens, S. Vermeire, and Y. Vanrenterghem The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152 T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients Clin Pharmacol Ther 78 2005 351 361
70. A. Kwara, M. Lartey, I. Boamah, N.L. Rezk, J. Oliver-Commey, and E. Kenu Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation J Clin Pharmacol 49 2009 1079 1090
71. A. Kwara, M. Lartey, K.W. Sagoe, E. Kenu, and M.H. Court CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients AIDS 23 2009 2101 2106
72. J.W. Lampe, J. Bigler, A.C. Bush, and J.D. Potter Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y) Cancer Epidemiol Biomarkers Prev 9 2000 329 333
73. J.W. Lampe, J. Bigler, N.K. Horner, and J.D. Potter UDP- glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations Pharmacogenetics 9 1999 341 349
74. T.O. Lankisch, U. Moebius, M. Wehmeier, G. Behrens, M.P. Manns, and R.E. Schmidt Gilbert's disease and atazanavir: from phenotype to UDP- glucuronosyltransferase haplotype Hepatology 44 2006 1324 1332
75. T.O. Lankisch, C. Schulz, T. Zwingers, T.J. Erichsen, M.P. Manns, and V. Heinemann Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk Cancer Epidemiol Biomarkers Prev 17 2008 695 701
76. E. Levesque, M.O. Benoit-Biancamano, R. Delage, F. Couture, and C. Guillemette Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers Pharmacogenomics 9 2008 869 879
77. E. Levesque, R. Delage, M.O. Benoit-Biancamano, P. Caron, O. Bernard, and F. Couture The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers Clin Pharmacol Ther 81 2007 392 400
78. P.I. Mackenzie, K.W. Bock, B. Burchell, C. Guillemette, S. Ikushiro, and T. Iyanagi Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily Pharmacogenet Genomics 15 2005 677 685
79. P. Madadi, C.J. Ross, M.R. Hayden, B.C. Carleton, A. Gaedigk, and J.S. Leeder Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study Clin Pharmacol Ther 85 1 2009 31 35
80. R.H. Mathijssen, F.A. de Jong, R.H. van Schaik, E.R. Lepper, L.E. Friberg, and T. Rietveld Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes J Natl Cancer Inst 96 2004 1585 1592
81. R.H. Mathijssen, S. Marsh, M.O. Karlsson, R. Xie, S.D. Baker, and J. Verweij Irinotecan pathway genotype analysis to predict pharmacokinetics Clin Cancer Res 9 2003 3246 3253
82. R. Meech, J.O. Miners, B.C. Lewis, and P.I. Mackenzie The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily Pharmacol Ther 134 2012 200 218
83. V. Menard, O. Eap, M. Harvey, C. Guillemette, and E. Levesque Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism Hum Mutat 30 2009 1310 1319
84. J.O. Miners, K. Bowalgaha, D.J. Elliot, P. Baranczewski, and K.M. Knights Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation Drug Metab Dispos 39 2011 644 652
85. J.O. Miners, P.I. Mackenzie, and K.M. Knights The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential Drug Metab Rev 42 2010 196 208
86. A. Mori, Y. Maruo, M. Iwai, H. Sato, and Y. Takeuchi UDP- glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation Drug Metab Dispos 33 2005 672 675
87. A. Nakamura, M. Nakajima, H. Yamanaka, R. Fujiwara, and T. Yokoi Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines Drug Metab Dispos 36 2008 1461 1464
88. S.L. Navarro, Y. Chen, L. Li, S.S. Li, J.L. Chang, and Y. Schwarz UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables Drug Metab Dispos 39 2011 1650 1657
89. M. Neely, L. Decosterd, A. Fayet, J.S. Lee, A. Margol, and M. Kanani Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers Antimicrob Agents Chemother 54 2010 4619 4625
90. M. Nozawa, T. Ohnuma, Y. Matsubara, Y. Sakai, T. Hatano, and R. Hanzawa The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP) Ther Drug Monit 30 2008 35 40
91. S. Ohno, and S. Nakajin Quantitative analysis of UGT2B28 mRNA expression by real-time RT-PCR and application to human tissue distribution study Drug Metab Lett 5 2011 202 208
92. L. Paoluzzi, A.S. Singh, D.K. Price, R. Danesi, R.H. Mathijssen, and J. Verweij Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 J Clin Pharmacol 44 2004 854 860
93. C.J. Peer, T.M. Sissung, A. Kim, L. Jain, S. Woo, and E.R. Gardner Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia Clin Cancer Res 18 2012 2099 2107
94. N. Picard The pharmacokinetic interaction between mycophenolic acid and cyclosporine revisited: a commentary on "Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus" Xenobiotica 43 2013 836 838
95. N. Picard, D. Ratanasavanh, A. Premaud, Y. Le Meur, and P. Marquet Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism Drug Metab Dispos 33 2005 139 146
96. R.K. Portenoy, H.T. Thaler, C.E. Inturrisi, H. Friedlander-Klar, and K.M. Foley The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function Clin Pharmacol Ther 51 1992 422 431
97. T. Prueksaritanont, R. Subramanian, X. Fang, B. Ma, Y. Qiu, and J.H. Lin Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization Drug Metab Dispos 30 2002 505 512
98. S. Riedmaier, K. Klein, U. Hofmann, J.E. Keskitalo, P.J. Neuvonen, and M. Schwab UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo Clin Pharmacol Ther 87 2010 65 73
99. S. Rodriguez-Novoa, L. Martin-Carbonero, P. Barreiro, G. Gonzalez-Pardo, I. Jimenez-Nacher, and J. Gonzalez-Lahoz Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia AIDS 21 2007 41 46
100. M. Rotger, P. Taffe, G. Bleiber, H.F. Gunthard, H. Furrer, and P. Vernazza Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia J Infect Dis 192 2005 1381 1386
101. A. Rowland, D.J. Elliot, J.A. Williams, P.I. Mackenzie, R.G. Dickinson, and J.O. Miners In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction Drug Metab Dispos 34 2006 1055 1062
102. M. Saeki, Y. Saito, H. Jinno, K. Sai, A. Hachisuka, and N. Kaniwa Genetic variations and haplotypes of UGT1A4 in a Japanese population Drug Metab Pharmacokinet 20 2005 144 151
103. K. Sai, M. Saeki, Y. Saito, S. Ozawa, N. Katori, and H. Jinno UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer Clin Pharmacol Ther 75 2004 501 515
104. Y. Saito, K. Maekawa, S. Ozawa, and J. Sawada Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other ethnic populations Curr Pharmacogenomics 5 2007 49 78
105. Y. Saito, K. Sai, K. Maekawa, N. Kaniwa, K. Shirao, and T. Hamaguchi Close association of UGT1A9 IVS1+399C>T with UGT1A1*28,*6, or*60 haplotype and its apparent influence on 7-ethyl-10- hydroxycamptothecin (SN-38) glucuronidation in Japanese Drug Metab Dispos 37 2009 272 276
106. E. Sandanaraj, S.R. Jada, X. Shu, R. Lim, S.C. Lee, and Q. Zhou Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients Pharmacogenomics J 8 2008 174 185
107. M.B. Sawyer, F. Innocenti, S. Das, C. Cheng, J. Ramirez, and F.H. Pantle-Fisher A pharmacogenetic study of uridine diphosphate- glucuronosyltransferase 2B7 in patients receiving morphine Clin Pharmacol Ther 73 2003 566 574
108. M. Siccardi, A. D'Avolio, S. Rodriguez-Novoa, L. Cuenca, M. Simiele, and L. Baietto Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting Ther Drug Monit 34 2012 232 235
109. C.F. Stewart, J.C. Panetta, M.A. O'Shaughnessy, S.L. Throm, C.H. Fraga, and T. Owens UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan J Clin Oncol 25 2007 2594 2600
110. J.C. Stingl, J. Brockmoller, and R. Viviani Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function Mol Psychiatry 18 2013 273 287
111. F. Stringer, B.A. Ploeger, J. DeJongh, G. Scott, R. Urquhart, and A. Karim Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar J Clin Pharmacol 53 2013 256 263
112. F. Stringer, G. Scott, M. Valbuena, J. Kinley, M. Nishihara, and R. Urquhart The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent Eur J Clin Pharmacol 69 2013 423 430
113. A.J. Sutton, K.R. Abrams, D.R. Jones, T.A. Sheldon, and F. Song Methods for Meta-analysis in Medical Research 2000 John Wiley & Sons Chichester
114. J.J. Swen, T.W. Huizinga, H. Gelderblom, E.G. de Vries, W.J. Assendelft, and J. Kirchheiner Translating pharmacogenomics: challenges on the road to the clinic PLoS Med 4 2007 e209
115. J.J. Swen, M. Nijenhuis, A. de Boer, L. Grandia, A.H. Maitland-van der Zee, and H. Mulder Pharmacogenetics: from bench to byte - an update of guidelines Clin Pharmacol Ther 89 2011 662 673
116. Y. Takekuma, T. Takenaka, M. Kiyokawa, K. Yamazaki, H. Okamoto, and A. Kitabatake Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol J Pharm Pharm Sci 9 2006 101 112
117. J. Tankanitlert, N.P. Morales, T.A. Howard, P. Fucharoen, R.E. Ware, and S. Fucharoen Effects of combined UDP-glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on paracetamol pharmacokinetics in beta-thalassemia/HbE Pharmacology 79 2007 97 103
118. S.G. Thompson, and S.J. Pocock Can meta-analyses be trusted? Lancet 338 1991 1127 1130
119. G. Toffoli, E. Cecchin, G. Corona, A. Russo, A. Buonadonna, and M. D'Andrea The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer J Clin Oncol 24 2006 3061 3068
120. R.H. Tukey, C.P. Strassburg, and P.I. Mackenzie Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity Mol Pharmacol 62 2002 446 450
121. C. Ulens, L. Baker, A. Ratka, D. Waumans, and J. Tytgat Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies Biochem Pharmacol 62 2001 1273 1282
122. M. van Agteren, V.W. Armstrong, R.H. van Schaik, H. de Fijter, A. Hartmann, and M. Zeier AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism Ther Drug Monit 30 2008 439 444
123. M.G. van Oijen, C. Barthelemy, M.J. Janssen, E. Joiris, W.H. Peters, and R.J. Laheij Effect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers Pharmacology 83 2009 237 242
124. R.H. van Schaik, M. van Agteren, J.W. de Fijter, A. Hartmann, J. Schmidt, and K. Budde UGT1A9-275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients Clin Pharmacol Ther 86 2009 319 327
125. Y.H. Wang, M. Trucksis, J.J. McElwee, P.H. Wong, C. Maciolek, and C.D. Thompson UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study Clin Pharmacol Ther 92 2012 96 102
126. L.A. Wenning, A.S. Petry, J.T. Kost, B. Jin, S.A. Breidinger, and I. DeLepeleire Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms Clin Pharmacol Ther 85 2009 623 627
127. E. Wieland, M. Shipkova, U. Schellhaas, E. Schutz, P.D. Niedmann, and V.W. Armstrong Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 33 2000 107 113
128. J.A. Williams, R. Hyland, B.C. Jones, D.A. Smith, S. Hurst, and T.C. Goosen Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios Drug Metab Dispos 32 2004 1201 1208
129. A. Yamada, K. Maeda, N. Ishiguro, Y. Tsuda, T. Igarashi, and T. Ebner The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers Pharmacogenet Genomics 21 2011 523 530
130. H. Yamanaka, M. Nakajima, M. Katoh, Y. Hara, O. Tachibana, and J. Yamashita A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity Pharmacogenetics 14 2004 329 332
131. D. Zhang, T.J. Chando, D.W. Everett, C.J. Patten, S.S. Dehal, and W.G. Humphreys In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation Drug Metab Dispos 33 2005 1729 1739
132. W.X. Zhang, B. Chen, Z. Jin, Z. Yu, X. Wang, and H. Chen Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients Xenobiotica 38 2008 1422 1436
133. Z. Zheng, J.Y. Park, C. Guillemette, S.P. Schantz, and P. Lazarus Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk J Natl Cancer Inst 93 2001 1411 1418
134. Q. Zhou, A. Sparreboom, E.H. Tan, Y.B. Cheung, A. Lee, and D. Poon Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer Br J Clin Pharmacol 59 2005 415 424
135. A. Alonen, O. Aitio, K. Hakala, L. Luukkanen, M. Finel, and R. Kostiainen Biosynthesis of dobutamine monoglucuronides and glucuronidation of dobutamine by recombinant human UDP-glucuronosyltransferases Drug Metab Dispos 33 2005 657 663
136. A. Alonen, M. Finel, and R. Kostiainen The human UDP- glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan Biochem Pharmacol 76 2008 763 772
137. U.A. Argikar, and R.P. Remmel Variation in glucuronidation of lamotrigine in human liver microsomes Xenobiotica 39 2009 355 363
138. S.K. Bae, Y.J. Jeong, C. Lee, and K.H. Liu Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites Xenobiotica 41 2011 437 444
139. O. Barbier, D. Turgeon, C. Girard, M.D. Green, T.R. Tephly, and D.W. Hum 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7) Drug Metab Dispos 28 2000 497 502
140. M.O. Benoit-Biancamano, J. Connelly, L. Villeneuve, P. Caron, and C. Guillemette Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants Drug Metab Dispos 37 2009 322 329
141. O. Bernard, J. Tojcic, K. Journault, L. Perusse, and C. Guillemette Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid Drug Metab Dispos 34 2006 1539 1545
142. A.S. Blevins-Primeau, D. Sun, G. Chen, A.K. Sharma, C.J. Gallagher, and S. Amin Functional significance of UDP-glucuronosyltransferase variants in the
143. K. Bourcier, R. Hyland, S. Kempshall, R. Jones, J. Maximilien, and N. Irvine Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes Drug Metab Dispos 38 2010 923 929
144. K. Bourcier, R. Hyland, S. Kempshall, R. Jones, J. Maximilien, and N. Irvine Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes Drug Metab Dispos 38 2012 923 929
145. K. Bowalgaha, D.J. Elliot, P.I. Mackenzie, K.M. Knights, S. Swedmark, and J.O. Miners S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen Br J Clin Pharmacol 60 2005 423 433
146. U. Breyer-Pfaff, U. Mey, M.D. Green, and T.R. Tephly Comparative N-glucuronidation kinetics of ketotifen and amitriptyline by expressed human UDP-glucuronosyltransferases and liver microsomes Drug Metab Dispos 28 2000 869 872
147. G. Chen, N.E. Giambrone Jr., D.F. Dluzen, J.E. Muscat, A. Berg, and C.J. Gallagher Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms Cancer Res 70 2010 7543 7552
148. G. Chen, N.E. Giambrone Jr., D.F. Dluzen, J.E. Muscat, A. Berg, and C.J. Gallagher Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms Cancer Res 70 2012 7543 7552
149. M. Chen, B. LeDuc, S. Kerr, D. Howe, and D.A. Williams Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol Drug Metab Dispos 38 2010 368 375
150. S. Chouinard, M. Tessier, G. Vernouillet, S. Gauthier, F. Labrie, and O. Barbier Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue Mol Pharmacol 69 2006 908 920
151. B.L. Coffman, W.R. Kearney, M.D. Green, R.G. Lowery, and T.R. Tephly Analysis of opioid binding to UDP-glucuronosyltransferase 2B7 fusion proteins using nuclear magnetic resonance spectroscopy Mol Pharmacol 59 2001 1464 1469
152. M.H. Court Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases Methods Enzymol 400 2005 104 116
153. M.H. Court Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system Drug Metab Rev 42 2010 209 224
154. M.H. Court, S. Krishnaswamy, Q. Hao, S.X. Duan, C.J. Patten, and L.L. Von Moltke Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism Drug Metab Dispos 31 2003 1125 1133
155. S. Crettol, J.J. Deglon, J. Besson, M. Croquette-Krokar, R. Hammig, and I. Gothuey ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment Clin Pharmacol Ther 80 2006 668 681
156. D.S. Darbari, R.H. van Schaik, E.V. Capparelli, S. Rana, R. McCarter, and J. van den Anker UGT2B7 promoter variant -840G> A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease Am J Hematol 83 2008 200 202
157. N.M. Davies, X.W. Teng, and N.M. Skjodt Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor Clin Pharmacokinet 42 2003 545 556
158. T. Ebner, R.P. Remmel, and B. Burchell Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol Mol Pharmacol 43 1993 649 654
159. T. Ebner, K. Wagner, and W. Wienen Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity Drug Metab Dispos 38 2010 1567 1575
160. K.K. Erickson-Ridout, D. Sun, and P. Lazarus Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)(7)TAA and UGT1A4 L48V polymorphisms Pharmacogenet Genomics 22 2012 561 576
161. B.T. Ethell, G.D. Anderson, and B. Burchell The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP- glucuronosyltransferases Biochem Pharmacol 65 2003 1441 1449
162. K.A. Findlay, E. Kaptein, T.J. Visser, and B. Burchell Characterization of the uridine diphosphate-glucuronosyltransferase-catalyzing thyroid hormone glucuronidation in man J Clin Endocrinol Metab 85 2000 2879 2883
163. H. Fujino, I. Yamada, S. Shimada, M. Yoneda, and J. Kojima Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization Xenobiotica 33 2003 27 41
164. A.L. Gagez, K. Rouguieg-Malki, F.L. Sauvage, P. Marquet, and N. Picard Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry Anal Biochem 427 2012 52 59
165. F. Geng, Z. Jiao, Y.J. Dao, X.Y. Qiu, J.J. Ding, and X.J. Shi The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals Clin Chim Acta 413 2012 683 690
166. A. Ghosal, N. Hapangama, Y. Yuan, J. Achanfuo-Yeboah, R. Iannucci, and S. Chowdhury Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia) Drug Metab Dispos 32 2004 314 320
167. A. Ghosal, Y. Yuan, N. Hapangama, A.D. Su, N. Alvarez, and S.K. Chowdhury Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine Biopharm Drug Dispos 25 2004 243 252
168. M.D. Green, G. Belanger, D.W. Hum, A. Belanger, and T.R. Tephly Glucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein Drug Metab Dispos 25 1997 1389 1394
169. M.D. Green, W.P. Bishop, and T.R. Tephly Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides Drug Metab Dispos 23 1995 299 302
170. M.D. Green, C.D. King, B. Mojarrabi, P.I. Mackenzie, and T.R. Tephly Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3 Drug Metab Dispos 26 1998 507 512
171. N. Hanioka, K. Hayashi, T. Shimizudani, K. Nagaoka, A. Koeda, and S. Naito Stereoselective glucuronidation of propranolol in human and cynomolgus monkey liver microsomes: role of human hepatic UDP-glucuronosyltransferase isoforms, UGT1A9, UGT2B4 and UGT2B7 Pharmacology 82 2008 293 303
172. N. Hanioka, S. Ozawa, H. Jinno, M. Ando, Y. Saito, and J. Sawada Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin Xenobiotica 31 2001 687 699
173. R. Hyland, T. Osborne, A. Payne, S. Kempshall, Y.R. Logan, and K. Ezzeddine In vitro and in vivo glucuronidation of midazolam in humans Br J Clin Pharmacol 67 2009 445 454
174. F. Innocenti, L. Iyer, J. Ramirez, M.D. Green, and M.J. Ratain Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7 Drug Metab Dispos 29 2001 686 692
175. F. Innocenti, S.D. Undevia, L. Iyer, P.X. Chen, S. Das, and M. Kocherginsky Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 2004 1382 1388
176. K. Inoue, M. Miura, S. Satoh, H. Kagaya, M. Saito, and T. Habuchi Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients Ther Drug Monit 29 2007 299 304
177. K. Itaaho, M.H. Court, P. Uutela, R. Kostiainen, A. Radominska-Pandya, and M. Finel Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10 Drug Metab Dispos 37 2009 768 775
178. C. Jin, J.O. Miners, K.J. Lillywhite, and P.I. Mackenzie Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs J Pharmacol Exp Ther 264 1993 475 479
179. M.S. Joy, T. Boyette, Y. Hu, J. Wang, M. La, and S.L. Hogan Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis Eur J Clin Pharmacol 66 2010 1119 1130
180. H. Kagaya, K. Inoue, M. Miura, S. Satoh, M. Saito, and H. Tada Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients Eur J Clin Pharmacol 63 2007 279 288
181. S. Kaivosaari, P. Toivonen, O. Aitio, J. Sipila, M. Koskinen, and J.S. Salonen Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes Drug Metab Dispos 36 2008 1529 1537
182. T. Kaku, K. Ogura, T. Nishiyama, T. Ohnuma, K. Muro, and A. Hiratsuka Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4 Biochem Pharmacol 67 2004 2093 2102
183. L.K. Kamdem, Y. Liu, V. Stearns, S.A. Kadlubar, J. Ramirez, and S. Jeter In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole Br J Clin Pharmacol 70 2010 854 869
184. S.P. Kang, J. Ramirez, L. House, W. Zhang, S. Mirkov, and W. Liu A pharmacogenetic study of vorinostat glucuronidation Pharmacogenet Genomics 20 2010 638 641
185. Y. Kato, T. Izukawa, S. Oda, T. Fukami, M. Finel, and T. Yokoi Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4 Drug Metab Dispos 41 2013 1389 1397
186. Y. Kato, M. Nakajima, S. Oda, T. Fukami, and T. Yokoi Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution Drug Metab Dispos 40 2012 240 248
187. O. Kerdpin, K.M. Knights, D.J. Elliot, and J.O. Miners In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway Biochem Pharmacol 76 2008 249 257
188. P.J. Kilford, R. Stringer, B. Sohal, J.B. Houston, and A. Galetin Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes Drug Metab Dispos 37 2009 82 89
189. L.C. Kirkwood, R.L. Nation, and A.A. Somogyi Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors Clin Exp Pharmacol Physiol 25 1998 266 270
190. K.M. Knights, L.K. Winner, D.J. Elliot, K. Bowalgaha, and J.O. Miners Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs Br J Clin Pharmacol 68 2009 402 412
191. T. Koga, R. Fujiwara, M. Nakajima, and T. Yokoi Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes Drug Metab Dispos 39 2011 54 60
192. T. Kubota, B.C. Lewis, D.J. Elliot, P.I. Mackenzie, and J.O. Miners Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4 Mol Pharmacol 72 2007 1054 1062
193. G.E. Kuehl, J.W. Lampe, J.D. Potter, and J. Bigler Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes Drug Metab Dispos 33 2005 1027 1035
194. G.E. Kuehl, and S.E. Murphy N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP- glucuronosyltransferases Drug Metab Dispos 31 2003 1361 1368
195. P. Lautala, B.T. Ethell, J. Taskinen, and B. Burchell The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases Drug Metab Dispos 28 2000 1385 1389
196. I. Laverdiere, P. Caron, M. Harvey, E. Levesque, and C. Guillemette In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4 Drug Metab Dispos 39 2011 1127 1130
197. P. Lehtonen, T. Sten, O. Aitio, M. Kurkela, K. Vuorensola, and M. Finel Glucuronidation of racemic O-desmethyltramadol, the active metabolite of tramadol Eur J Pharm Sci 41 2010 523 530
198. L.M. Limenta, T. Jirasomprasert, J. Tankanitlert, S. Svasti, P. Wilairat, and U. Chantharaksri UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers Br J Clin Pharmacol 65 2008 908 916
199. A.I. Loureiro, C. Fernandes-Lopes, M.J. Bonifacio, L.C. Wright, and P. Soares-da-Silva Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation Drug Metab Dispos 39 2011 1486 1494
200. H. Lu, X. Meng, C. Li, S. Sang, C. Patten, and S. Sheng Glucuronides of tea catechins: enzymology of biosynthesis and biological activities Drug Metab Dispos 31 2003 452 461
201. A. Lundahl, H. Lennernas, L. Knutson, U. Bondesson, and M. Hedeland Identification of finasteride metabolites in human bile and urine by high-performance liquid chromatography/tandem mass spectrometry Drug Metab Dispos 37 2009 2008 2017
202. L. Luukkanen, J. Taskinen, M. Kurkela, R. Kostiainen, J. Hirvonen, and M. Finel Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases Drug Metab Dispos 33 2005 1017 1026
203. L. Ma, J. Sun, Y. Peng, R. Zhang, F. Shao, and X. Hu Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform Drug Metab Dispos 40 2012 734 741
204. P.I. Mackenzie Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid Ther Drug Monit 22 2000 10 13
205. Y. Mano, T. Usui, and H. Kamimura Contribution of UDP- glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver Eur J Clin Pharmacol 63 2007 289 296
206. M. Mao, E. Skogh, M.G. Scordo, and M.L. Dahl Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid J Clin Psychopharmacol 32 2012 287 289
207. A. Mazur, C.F. Lichti, P.L. Prather, A.K. Zielinska, S.M. Bratton, and A. Gallus-Zawada Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids Drug Metab Dispos 37 2009 1496 1504
208. K.A. McGurk, C.H. Brierley, and B. Burchell Drug glucuronidation by human renal UDP-glucuronosyltransferases Biochem Pharmacol 55 1998 1005 1012
209. M. Miura, T. Niioka, S. Kato, H. Kagaya, M. Saito, and T. Habuchi Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation Ther Drug Monit 33 2011 295 302
210. G.A. Morrish, D.J. Foster, and A.A. Somogyi Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids Br J Clin Pharmacol 61 2006 326 335
211. M. Nakajima, N. Sakata, N. Ohashi, T. Kume, and T. Yokoi Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4′-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes Drug Metab Dispos 30 2002 1250 1256
212. M. Nakajima, E. Tanaka, T. Kobayashi, N. Ohashi, T. Kume, and T. Yokoi Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms Drug Metab Dispos 30 2002 636 642
213. E. Ngaimisi, A. Habtewold, O. Minzi, E. Makonnen, S. Mugusi, and W. Amogne Importance of ethnicity, CYP2B6 and ABCB1 genotype for Efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two Sub-Saharan Africa populations PLoS One 8 2013 e67946
214. T. Nishiyama, T. Kobori, K. Arai, K. Ogura, T. Ohnuma, and K. Ishii Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone Arch Biochem Biophys 454 2006 72 79
215. A. Ohno, Y. Saito, N. Hanioka, H. Jinno, M. Saeki, and M. Ando Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol Drug Metab Dispos 32 2004 235 239
216. W.B. Park, P.G. Choe, K.H. Song, J.H. Jeon, S.W. Park, and H.B. Kim Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency Clin Infect Dis 51 2010 101 106
217. T. Prueksaritanont, C. Tang, Y. Qiu, L. Mu, R. Subramanian, and J.H. Lin Effects of fibrates on metabolism of statins in human hepatocytes Drug Metab Dispos 30 2002 1280 1287
218. Y.G. Puranik, A.K. Birnbaum, S.E. Marino, G. Ahmed, J.C. Cloyd, and R.P. Remmel Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy Pharmacogenomics 14 2013 35 45
219. P. Raungrut, V. Uchaipichat, D.J. Elliot, B. Janchawee, A.A. Somogyi, and J.O. Miners In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans J Pharmacol Exp Ther 334 2010 609 618
220. K. Rouguieg, N. Picard, F.L. Sauvage, J.M. Gaulier, and P. Marquet Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes Drug Metab Dispos 38 2010 40 45
221. K. Sakaguchi, M. Green, N. Stock, T.S. Reger, J. Zunic, and C. King Glucuronidation of carboxylic acid containing compounds by UDP- glucuronosyltransferase isoforms Arch Biochem Biophys 424 2004 219 225
222. A.I. Sanchez-Fructuoso, M.L. Maestro, N. Calvo, M. Viudarreta, I. Perez-Flores, and S. Veganzone The prevalence of uridine diphosphate- glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152 T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients Transplant Proc 41 2009 2313 2316
223. K.A. Seo, S.K. Bae, Y.K. Choi, C.S. Choi, K.H. Liu, and J.G. Shin Metabolism of 1′- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7 Drug Metab Dispos 38 2010 2007 2013
224. H.S. Smith Opioid metabolism Mayo Clin Proc 84 2009 613 624
225. A.G. Staines, M.W. Coughtrie, and B. Burchell N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7 J Pharmacol Exp Ther 311 2004 1131 1137
226. T. Sten, I. Bichlmaier, T. Kuuranne, A. Leinonen, J. Yli-Kauhaluoma, and M. Finel UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly Drug Metab Dispos 37 2009 417 423
227. A.N. Stone, P.I. Mackenzie, A. Galetin, J.B. Houston, and J.O. Miners Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7 Drug Metab Dispos 31 2003 1086 1089
228. D. Sun, G. Chen, R.W. Dellinger, A.K. Sharma, and P. Lazarus Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics Pharmacogenet Genomics 20 2010 575 585
229. D. Sun, N.R. Jones, A. Manni, and P. Lazarus Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo Cancer Prev Res (Phila) 6 2013 719 730
230. M. Tachibana, M. Tanaka, Y. Masubuchi, and T. Horie Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes Drug Metab Dispos 33 2005 803 811
231. J. Tojcic, M.O. Benoit-Biancamano, M.H. Court, R.J. Straka, P. Caron, and C. Guillemette In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes Drug Metab Dispos 37 2009 2236 2243
232. V. Uchaipichat, P.I. Mackenzie, D.J. Elliot, and J.O. Miners Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases Drug Metab Dispos 34 2006 449 456
233. V. Uchaipichat, C. Suthisisang, and J.O. Miners The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs Drug Metab Dispos 41 2013 1273 1284
234. H. Wang, L. Yuan, and S. Zeng Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen Biochem Pharmacol 82 2011 1757 1763
235. Y. Watanabe, M. Nakajima, N. Ohashi, T. Kume, and T. Yokoi Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1 Drug Metab Dispos 31 2003 589 595
236. Z. Wen, M.N. Tallman, S.Y. Ali, and P.C. Smith UDP- glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics Drug Metab Dispos 35 2007 371 380
237. L. Yu, S. Lu, Y. Lin, and S. Zeng Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases Biochem Pharmacol 73 2007 1842 1851
238. L. Yu, M. Qian, Y. Liu, T. Yao, and S. Zeng Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9 Chirality 22 2010 456 461
239. W. Zhao, M. Fakhoury, G. Deschenes, G. Roussey, K. Brochard, and P. Niaudet Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients J Clin Pharmacol 50 2010 1280 1291
240. D. Zhou, J. Guo, A.J. Linnenbach, C.L. Booth-Genthe, and S.W. Grimm Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine Drug Metab Dispos 38 2010 863 870